氯苯醇酸铵乙酯盐酸盐 | 1164-38-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 氯苯醇酸铵乙酯盐酸盐
• 英文名称: Lachesine chloride
• 英文别名: ethyl-(2-benziloyloxy-ethyl)-dimethyl-ammonium; chloride；Aethyl-(2-benziloyloxy-aethyl)-dimethyl-ammonium; Chlorid；lachesine；lachesin；ethyl-[2-(2-hydroxy-2,2-diphenylacetyl)oxyethyl]-dimethylazanium;chloride
• CAS: 1164-38-1
• 化学式: C₂₀H₂₆NO₃*Cl
• 分子量: 363.884
• InChiKey: TVCAZGSWNBZVJN-UHFFFAOYSA-M

物化性质

• 熔点：
  213°

计算性质

• 辛醇/水分配系数(LogP)：
  -0.43
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  二苯基乙醇酸钾 在 丙酮 作用下， 生成 氯苯醇酸铵乙酯盐酸盐
  参考文献：
  名称：

  Ford-Moore; Ing, Journal of the Chemical Society, 1947, p. 59

  摘要：

  DOI：

文献信息

• Pulmonary delivery for bioconjugation
  申请人：CONJUCHEM, INC.

  公开号：US20040156859A1

  公开（公告）日：2004-08-12

  Methods of and compositions for pulmonary delivery of therapeutic agents which are capable of forming covalent bonds with a site of interest or which have formed a covalent bond with a pulmonary solution protein are disclosed. Therapeutic agents useful in the invention include wound healing agents, antibiotics, anti-inflammatories, anti-oxidants, anti-proliferatives, immunosupressants, anti-infective and anti-cancer agents.

  本发明公开了一种可与感兴趣的部位形成共价键或已与肺溶液蛋白形成共价键的治疗剂的肺部输送方法和组成物。本发明中有用的治疗剂包括伤口愈合剂、抗生素、抗炎剂、抗氧化剂、抗增殖剂、免疫抑制剂、抗感染和抗癌剂。
• A method of preserving ophthalmic solutions and compositions therefor
  申请人：CIBA-GEIGY AG

  公开号：EP0354186A1

  公开（公告）日：1990-02-07

  A preservative for ophthalmic solutions having an active ingredient is provided, having a hydrogen peroxide content of about 0.001 % to about 0.10 % by weight; and diethylene triamine penta(methylene phosphonic acid), or a physiologically compatible salt thereof, present at about 0.002 % to 0.03 % by weight and/or 0.005 % to about 0.20 % by weight of 1-hydroxyethylidene-1,1-diphosphonic acid, or a physiologically compatible salt thereof.

  提供了一种用于具有活性成分的眼科溶液的防腐剂，其过氧化氢含量约为 0.001 % 至约 0.10 %（按重量计）；二亚乙基三胺五亚甲基膦酸或其生理相容盐的含量约为 0.002 % 至 0.03 %（按重量计）和/或 0.005 % 至约 0.20 %（按重量计），1-羟基亚乙基-1,1-二膦酸或其生理相容盐的含量约为 0.002 % 至 0.03 %（按重量计）和/或 0.005 % 至约 0.20 %（按重量计）。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• Method for treating pharmaceutical compositions
  申请人：——

  公开号：US20020103196A1

  公开（公告）日：2002-08-01

  The invention provides stabilized ophthalmic compositions and methods for stabilizing ophthalmic compositions.

  本发明提供了稳定的眼科组合物和稳定眼科组合物的方法。
• Stabilized hyrogen peroxide solutions
  申请人：——

  公开号：US20020127281A1

  公开（公告）日：2002-09-12

  Provided are stabilized aqueous solutions containing low concentrations of hydrogen peroxide as a preservative. Such solutions are effectively stabilized at pH>8 by the use of certain biocompatible organophophorous compounds as chelating stabilizers. These ophthalmologically acceptable compositions are especially useful in buffered saline for eye care solutions either with or without ophthalmic medicinal agents.

  本发明提供了含有低浓度过氧化氢作为防腐剂的稳定水溶液。 通过使用某些生物相容性有机发泡化合物作为螯合稳定剂，可有效稳定 pH 值大于 8 的溶液。 这些眼科可接受成分尤其适用于含有或不含眼科药物的眼科护理缓冲盐溶液。